Nanocapsules with HIF-1-alpha Inhibitor for Treatment of Choroidal Neovascularization in a Rat Model
Maryland Shared Open Access Repository (USMAI Consortium) · 01.06.2023
DOI: 10.13016/m2vfec-y5cg ↗Kurz gefasst
Fachartikel in der Zeitschrift Maryland Shared Open Access Repository (USMAI Consortium), erschienen am 01.06.2023. Verfasst von Han und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Purpose
Choroidal neovascularization (CNV) is a vision-threatening complication of many retinal diseases, including age-related macular degeneration. Currently, the mainstay of CNV treatment is intravitreal delivery of antibodies that bind VEGF. However, there remains a great need for alternative therapies with longer duration and better treatment effect. This study describes the development of nanocapsule-based formulations toward sustained drug delivery of acriflavine (anti-angiogenic agent that inhibits hypoxia inducible factor [HIF]-1-alpha) and assesses its impact on CNV formation in a rat model.
Methods
Polyurethane nanocapsules were synthesized by an interfacial condensation polymerization reaction in a nanoemulsion. Acriflavine was mixed with isophorone diisocyanate in water and then applied in drop-wise fashion to the solution before lyophilization to form drug capsules. Wild type Brown Norway rats were treated with laser photocoagulation to induce CNV. Eyes were injected intravitreally on the same day with 10 ul of either acriflavine nanocapsules (5 ug total dose of acriflavine) or blank nanocapsules as controls. Animals were assessed at 14-days post-injection with fundus photography, fluorescein angiography, and OCT (Figure). Eyes were enucleated for immunohistochemical analysis. CNV formation was compared between eyes treated with acriflavine versus blank nanocapsules.
Results
Synthesis of acriflavine nanocapsules was reliable (Z-average diameter 197+/-39 nm) with a drug loading efficiency of 41 ug acriflavine/mg of nanocapsules. Following intravitreal injection, both nanocapsule formulations were well-tolerated, without signs of clinical inflammation or retinal toxicity. Visible intravitreal aggregates of nanocapsules were seen at 14-days post-injection. Preliminary qualitative analysis demonstrated markedly decreased sizes of CNV in acriflavine nanocapsules relative to fellow eye controls treated with blank nanocapsules (Figure).
Conclusions
Nanocapsule formulations with acriflavine can be reliably manufactured with consistent drug dosing. Acriflavine nanocapsules are well-tolerated after intravitreal injection in an in vivo rat model and shows promise for inhibiting CNV formation. Studies are ongoing to quantify the effect of CNV inhibition at different dosages as well as various time points to evaluate drug duration.
Schlagwörter
Zitieren
APA
Han, Ian, Pandala, N. G., Maisha, N., Ale, Tolulope, Mullins, R. F., Lavik, E., & Tucker, B. A. (2023). Nanocapsules with HIF-1-alpha Inhibitor for Treatment of Choroidal Neovascularization in a Rat Model. Maryland Shared Open Access Repository (USMAI Consortium). https://doi.org/10.13016/m2vfec-y5cg
Vancouver
Han, Ian, Pandala NG, Maisha N, Ale, Tolulope, et al. Nanocapsules with HIF-1-alpha Inhibitor for Treatment of Choroidal Neovascularization in a Rat Model. Maryland Shared Open Access Repository (USMAI Consortium). 2023. doi:10.13016/m2vfec-y5cg
BibTeX
@article{Han2023,
author = {Han and Ian and Pandala, Narendra G. and Maisha, Nuzhat and Ale and Tolulope and Mullins, Robert F. and Lavik, Erin and Tucker, Budd A.},
title = {Nanocapsules with HIF-1-alpha Inhibitor for Treatment of Choroidal Neovascularization in a Rat Model},
journal = {Maryland Shared Open Access Repository (USMAI Consortium)},
year = {2023},
doi = {10.13016/m2vfec-y5cg}
}
EUVIMED